ASCO Annual Meeting

Upper GI Cancers: Are We Getting Value for the Money?

Audrey Andrews

August 2011, Vol 2, No 5 - ASCO Annual Meeting

 

Upper GI Malignancies” was a plenary session at ASCO 2011, with 2 experts discussing whether results of recent clinical trials of targeted agents are clinically meaningful or just statistically positive, and what is the value of the enormous amount of money spent in treating noncolorectal gastrointestinal (GI) cancer.

Clinical versus Statistical Significance

 

Eileen Mary O’Reilly, MD, of Memorial Sloan-Kettering Cancer Center, examined some of the major trials.

[ Read More ]

Cost Considerations Change Dialogue

July/August 2010, Vol 1, No 3 - ASCO Annual Meeting

Although financial concerns are increasingly influencing choices in cancer therapy, barriers to cost discussions between physicians and patients often limit the scope of such discussions. Incentives for oncologists to use high-cost interventions and patients’ perceptions that cost consideration equates to second-class care are but 2 barriers to meaningful cost [ Read More ]